Home › Funds › MAVERICK CAPITAL LTD › PCVX
MAVERICK CAPITAL LTD position in PCVX
VAXCYTE INC · Health Care
MAVERICK CAPITAL LTD reported holding 1,613,242 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$93.8M, representing 0.87% of its reported portfolio and ranking #37 among its reported holdings. MAVERICK CAPITAL LTD has disclosed PCVX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MAVERICK CAPITAL LTD's PCVX position evolved
MAVERICK CAPITAL LTD first disclosed a stake in PCVX in Q1 2024 at 355,131 shares (US$24.3M). The position peaked in Q3 2024 at 976,249 shares, worth US$111.6M. Across 10 filings, MAVERICK CAPITAL LTD increased the stake 8 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,613,242 shares valued at US$93.8M — an increase of 235,504 shares quarter over quarter.. Notable position changes include a 94% increase in Q2 2024 (shares rose 51% over the following quarter), a 42% increase in Q3 2024 (shares fell 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 355.13K | $24.26M | New |
| Q2 2024 | 687.91K | $51.94M | Add |
| Q3 2024 | 976.25K | $111.56M | Add |
| Q4 2024 | 1.20M | $98.39M | Add |
| Q1 2025 | 1.21M | $45.62M | Add |
| Q2 2025 | 1.31M | $42.61M | Add |
| Q3 2025 | 1.29M | $46.45M | Reduce |
| Q4 2025 | 1.35M | $62.48M | Add |
| Q1 2026 | 1.38M | $80.06M | Add |
| Q2 2026 | 1.61M | $93.78M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 35 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M sh · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M sh · $249.96M · Q2 2026
- Kynam Capital Management, LP 2.92M sh · $169.88M · Q2 2026
- Caligan Partners LP 2.19M sh · $127.23M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M sh · $123.69M · Q2 2026
- Bellevue Group AG 1.97M sh · $114.63M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M sh · $82.86M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $80.23M · Q2 2026
More on MAVERICK CAPITAL LTD
FAQ
How long has MAVERICK CAPITAL LTD held PCVX?
MAVERICK CAPITAL LTD has disclosed PCVX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is MAVERICK CAPITAL LTD's current position in PCVX?
As of Q2 2026, MAVERICK CAPITAL LTD holds 1.61M shares of PCVX (VAXCYTE INC), valued at $93.78M, representing 0.87% of its reported portfolio and ranking #37.
Has MAVERICK CAPITAL LTD been buying or selling PCVX?
In the latest 13F filing (Q2 2026), MAVERICK CAPITAL LTD increased its position in PCVX. The position peaked in Q3 2024 at 976.25K shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.